{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:50:49Z","timestamp":1784389849624,"version":"3.55.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Overall response (OR) that combines complete (CR) and partial responses (PR) is the conventional end point for acute graft-versus-host disease (GVHD) trials. Because PR includes heterogeneous clinical presentations, reclassifying PR could produce a better end point. Patients in the primary treatment cohort from the Japanese Society for Transplantation and Cellular Therapy (JSTCT) were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated day 28 refined response (RR) criteria based on symptoms at treatment and day 28. We then evaluated RR for primary and second-line treatments, using the area under the receiver operating characteristic curve (AUC) and negative predictive value (NPV) for 6-month nonrelapse mortality as performance measures. RR considered patients with grade 0\/1 at day 28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC, 0.73 vs 0.69 [P &amp;lt; .001]; NPV, 92.0% vs 89.6% [P &amp;lt; .001]) and the Mount Sinai Acute GVHD International Consortium (MAGIC; AUC, 0.71 vs 0.68 [P = .032]; NPV, 90.9% vs 89.8% [P = .009]). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC, 0.64 vs 0.63 [P = .775]; NPV, 74.5% vs 66.0% [P &amp;lt; .001]) and MAGIC (AUC, 0.67 vs 0.64 [P = .105]; NPV, 86.8% vs 76.1% [P = .004]). Classifying persistent but mild skin symptoms as responses and residual lower gastrointestinal GVHD as nonresponses were major drivers in improving the prognostic performance of RR. Our externally validated day 28 RR would serve as a better end point than conventional criteria in future first- and second-line treatment trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016233","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:59:58Z","timestamp":1751367598000},"page":"4640-4653","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"},{"name":"2Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"},{"name":"3Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Therapy, Fujita Health University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spyrou","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"},{"name":"5Division of Emerging Medicine for Integrated Therapeutics, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-7843","authenticated-orcid":false,"given":"Marcio A.","family":"Diniz","sequence":"additional","affiliation":[{"name":"6Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY"},{"name":"7Department of Population Health Science and Policy, Institute for Health Care Delivery Science, Mount Sinai Health System at Mount Sinai, New York, NY"},{"name":"8Department of Population Health Science and Policy, The Tisch Cancer Institute, Biostatistics Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"10Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Choe","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Blood and Marrow Transplantation Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"12Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Etra","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"14Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"16Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"18Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"},{"name":"19Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[{"name":"20Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0850","authenticated-orcid":false,"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Vasova","sequence":"additional","affiliation":[{"name":"23Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2422","authenticated-orcid":false,"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-6083","authenticated-orcid":false,"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[{"name":"25Technical Department, Japanese Red Cross Blood Service Headquarters, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"26Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[{"name":"27Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"28Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"29Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan"},{"name":"30Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L. M.","family":"Ferrara","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"},{"name":"31Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-7828","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"16","key":"2025092310215830900_bib1","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1182\/bloodadvances.2023009885","article-title":"Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025092310215830900_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025092310215830900_bib3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2023020073","article-title":"Novel developments in the prophylaxis and treatment of acute GVHD","volume":"142","author":"Jamy","year":"2023","journal-title":"Blood"},{"issue":"25","key":"2025092310215830900_bib4","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"2025092310215830900_bib5","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025092310215830900_bib6","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2020007336","article-title":"Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness","volume":"136","author":"Mohty","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2025092310215830900_bib7","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood.2019000960","article-title":"How I treat steroid-refractory acute graft-versus-host disease","volume":"135","author":"Martin","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025092310215830900_bib8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bbmt.2015.12.024","article-title":"Improved treatment-related mortality and overall survival of patients with grade IV acute GVHD in the modern years","volume":"22","author":"El-Jawahri","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025092310215830900_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bjh.16540","article-title":"Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"190","author":"Akahoshi","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"2025092310215830900_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study","volume":"107","author":"Greinix","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"2025092310215830900_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2016.156356","article-title":"Improved survival after acute graft-versus-host disease diagnosis in the modern era","volume":"102","author":"Khoury","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"2025092310215830900_bib12","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/bloodadvances.2023012091","article-title":"Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis","volume":"8","author":"Akahoshi","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2025092310215830900_bib13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2025092310215830900_bib14","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(21)00367-7","article-title":"Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial","volume":"9","author":"Zeiser","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025092310215830900_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.2019003125","article-title":"Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial","volume":"135","author":"Pidala","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025092310215830900_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.2022017442","article-title":"Effective treatment of low-risk acute GVHD with itacitinib monotherapy","volume":"141","author":"Etra","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025092310215830900_bib17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood.2021015111","article-title":"A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","volume":"141","author":"Ponce","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2025092310215830900_bib18","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1182\/bloodadvances.2023009853","article-title":"Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease","volume":"7","author":"Al Malki","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2025092310215830900_bib19","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbmt.2009.08.003","article-title":"A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease","volume":"15","author":"Couriel","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2025092310215830900_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41409-020-01049-0","article-title":"Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease","volume":"56","author":"Kekre","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"2025092310215830900_bib21","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2025092310215830900_bib22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2025092310215830900_bib23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","article-title":"A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease","volume":"26","author":"Kebriaei","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2025092310215830900_bib24","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2017-11-815746","article-title":"\u03b11-antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease","volume":"131","author":"Magenau","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025092310215830900_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","article-title":"Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"26","key":"2025092310215830900_bib26","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2009-12-258442","article-title":"The best endpoint for acute GVHD treatment trials","volume":"115","author":"MacMillan","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2025092310215830900_bib27","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","article-title":"Graft-versus-host disease treatment: predictors of survival","volume":"16","author":"Levine","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025092310215830900_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2011.41","article-title":"Prognostic value of response after upfront therapy for acute GVHD","volume":"47","author":"Saliba","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2025092310215830900_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3324\/haematol.2013.093062","article-title":"Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease","volume":"99","author":"Inamoto","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"2025092310215830900_bib30","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2025092310215830900_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2019.220970","article-title":"Validation of Minnesota acute graft-versus-host disease risk score","volume":"105","author":"MacMillan","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"2025092310215830900_bib32","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2024012561","article-title":"The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD","volume":"8","author":"DeFilipp","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"2025092310215830900_bib33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbmt.2009.03.012","article-title":"Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement","volume":"15","author":"Martin","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025092310215830900_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"issue":"1","key":"2025092310215830900_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"3-4","key":"2025092310215830900_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.beha.2014.10.011","article-title":"Improved accuracy of acute graft-versus-host disease staging among multiple centers","volume":"27","author":"Levine","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2025092310215830900_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"2025092310215830900_bib38","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1182\/blood-2008-07-168401","article-title":"Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes","volume":"113","author":"Mielcarek","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025092310215830900_bib39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3348\/kjr.2024.0049","article-title":"Statistical methods for comparing predictive values in medical diagnosis","volume":"25","author":"Park","year":"2024","journal-title":"Korean J Radiol"},{"issue":"17","key":"2025092310215830900_bib40","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2023009929","article-title":"The utility of biomarkers in acute GVHD prognostication","volume":"7","author":"Spyrou","year":"2023","journal-title":"Blood Adv"},{"issue":"30","key":"2025092310215830900_bib41","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"2025092310215830900_bib42","author":"Breiman","year":"1984","edition":"1st ed"},{"issue":"3","key":"2025092310215830900_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"15","key":"2025092310215830900_bib44","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2025092310215830900_bib45","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/sim.6077","article-title":"Reclassification of predictions for uncovering subgroup specific improvement","volume":"33","author":"Biswas","year":"2014","journal-title":"Stat Med"},{"issue":"24","key":"2025092310215830900_bib46","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jnci\/djp394","article-title":"Re: discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk","volume":"101","author":"Spitz","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2025092310215830900_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12185-024-03772-6","article-title":"Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial","volume":"120","author":"Teshima","year":"2024","journal-title":"Int J Hematol"},{"issue":"23","key":"2025092310215830900_bib48","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","article-title":"The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease","volume":"3","author":"Srinagesh","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2025092310215830900_bib49","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood.2024025106","article-title":"Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD","volume":"144","author":"Akahoshi","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025092310215830900_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jtct.2024.01.079","article-title":"A day 14 endpoint for acute GVHD clinical trials","volume":"30","author":"Spyrou","year":"2024","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4640\/2412086\/blooda_adv-2025-016233-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4640\/2412086\/blooda_adv-2025-016233-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:34:52Z","timestamp":1758638092000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4640\/538040\/Refinement-of-day-28-treatment-response-criteria"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016233","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,12]]}}}